A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
2021
Precision Cancer Medicine
Preserved Fulltext
